The Role of Helicases in DNA Repair and Drug Discovery

Introduction: Why Helicases Are Becoming High-Value Drug Targets

Helicases—enzymes that unwind nucleic acid duplexes using ATP hydrolysis—sit at the heart of genome stability, innate immunity, transcription, and RNA biology. Initially viewed as textbook molecular machines, they have emerged as high-value therapeutic targets across oncology, virology, autoimmune disease, inflammatory disorders, and even age-associated degeneration. Their druggability is rapidly accelerating due to breakthroughs in structural biology, fragment screens, and biochemical high-throughput screening (HTS) technologies.

In parallel, advances in biochemical assay platforms have finally made robust helicase inhibitor discovery feasible. BellBrook Labs has played a central role in enabling this shift with two key HTS-validated platforms:

• Transcreener® ADP² Assay — a universal ATPase assay for detecting ADP produced during helicase-driven ATP hydrolysis
• Heliscreener™ Unwinding Assay — a fluorescence-based assay for measuring duplex unwinding directly

These complementary technologies allow researchers to interrogate helicase function from multiple angles: ATP turnover, RNA or DNA unwinding, or both. As a result, researchers can now perform primary screens, orthogonal confirmation, mechanism-of-action studies, and hit profiling in a single workflow.

In this article, we explore the pivotal role of helicases in DNA repair and drug discovery, highlight major helicase drug targets, and demonstrate how state-of-the-art biochemical assays accelerate the discovery of selective inhibitors.

What Are Helicases? A Quick Overview for Drug Discovery

Helicases are ubiquitous enzymes found in all organisms and classified into six superfamilies (SF1–SF6). Most human helicases fall into SF1 and SF2, which include numerous DEAD-box and DEAH-box helicases.

Core Functions Relevant to Drug Discovery

Helicases participate in:

• DNA repair and recombination
• Transcription and translation regulation
• RNA processing and splicing
• Innate immune sensing (e.g., RIG-I-like receptors)
• Genome maintenance and telomere stability
• Resolution of R-loops and G-quadruplexes
• Replication fork progression

Given this centrality, dysregulation or mutation of helicases contributes to:

• cancer initiation and progression
• immune dysregulation and autoinflammatory disease
• degenerative disorders
• premature aging syndromes
• viral replication cycles

This creates a wide therapeutic window for helicase-modulating drugs.

Helicases in DNA Repair: Essential Gatekeepers of Genome Stability

Many helicases directly participate in DNA damage response pathways, including:

• Homologous recombination (HR) – BLM, WRN, RECQL5, RTEL1, and FANCJ are essential for HR fidelity.
• Non-homologous end joining (NHEJ) – Helicases like POLQ facilitate end joining in HR-deficient tumors.
• Base excision and mismatch repair – Helicases govern damage scanning, strand displacement, and resolution.
• R-loop regulation – Helicases like DDX5, DHX9, and DDX21 resolve R-loops that contribute to replication stress.
• Telomere maintenance – WRN, BLM, and RTEL1 maintain telomere length and protect against catastrophic chromosome end fusion.

Disruption of these pathways leads to genomic instability—one of the most universal hallmarks of cancer. For this reason, DNA-repair helicases have become prime oncology targets, especially when exploited through synthetic lethality.

Major Helicase Drug Targets and Their Indications

Below is a consolidated list of the most prominent helicase drug targets, grouped by disease area. Targets supported by BellBrook platforms receive deeper coverage in later sections.

Oncology-Focused Helicase Targets

1. POLQ (DNA Polymerase Theta)

• Indications: HR-deficient cancers, BRCA1/2-mutated tumors, ovarian cancer, breast cancer
• Role: End-joining during microhomology-mediated repair
• Why it’s druggable: Synthetic lethality with BRCA mutations
• Assay relevance: Strong ATPase activity → excellent with Transcreener ADP²; also supports helicase unwinding assays.

2. WRN (Werner Syndrome Helicase)

• Indications: MSI-high cancers (FDA-recognized biomarker), colorectal cancer, gastric cancer
• Role: DNA replication stress mitigation, telomere stability
• Why it’s druggable: Required for survival of MSI-high tumors
• Assay relevance: Robust ATPase + unwinding activity; works in both Transcreener ADP and Heliscreener assays.

3. BLM (Bloom Syndrome Helicase)

• Indications: solid tumors, leukemia, cancers with replication stress
• Role: HR and replication fork maintenance
• Why it’s druggable: Synthetic-lethal vulnerabilities
• Assay relevance: Robust ATPase + unwinding activity; works in both Transcreener ADP and Heliscreener assays.

4. FANCJ (BRIP1)

• Indications: ovarian/breast cancers with Fanconi anemia pathway defects
• Role: interstrand crosslink repair
• Why it’s druggable: Vulnerable in tumors with FA mutations

5. DDX3X

• Indications: medulloblastoma, hepatocellular carcinoma, breast cancer
• Role: translation initiation, RNA processing, innate immunity
• Assay relevance: Robust ATPase + unwinding activity; works in both Transcreener ADP and Heliscreener assays.

6. DHX9 (RNA/DNA Helicase A)

• Indications: breast cancer, Ewing sarcoma, ovarian cancer, viral oncogenesis
• Role: R-loop resolution, transcription regulation
• Assay relevance: Robust ATPase + unwinding activity; works in both Transcreener ADP and Heliscreener assays.

Innate Immunity, Autoimmunity, and Antiviral Targets

7. RIG-I (DDX58)

• Indications: antiviral therapeutics, cancer immunotherapy
• Role: cytosolic dsRNA sensor that triggers type I interferon
• Druggability: Activation or allosteric modulation
• Assay relevance: ATPase activity → compatible with Transcreener ADP².

8. MDA5 (IFIH1)

• Indications: autoimmune disorders (Aicardi–Goutières), antiviral drug discovery
• Role: recognition of long dsRNA
• Assay relevance: Works with ADP² assays for ATP turnover measurement.

9. DDX41

• Indications: innate immunity, inflammasome-mediated disease, myeloid leukemia
• Role: DNA sensing
• Assay relevance: ATPase activity measurable via Transcreener.

Developmental Disorders and Rare Disease Targets

10. RECQL4

• Indications: Rothmund–Thomson syndrome, osteosarcoma risk
• Role: replication initiation and repair

11. RTEL1

• Indications: bone marrow failure, Hoyeraal–Hreidarsson syndrome
• Role: telomere maintenance

12. DDX21, DDX17, DDX1

• Indications: transcriptional dysregulation, neural disorders, viral replication
• Assay relevance: Works with ADP² assays for ATP turnover measurement.

These helicases are not yet major drug targets but are gaining attention in genetic and epigenetic disease mechanisms.

Why Helicases Are High-Potential Targets for Modern Drug Discovery

1. Synthetic Lethality Creates New Therapeutic Windows

Tumors with BRCA1/2 loss, mismatch repair deficiency, or Aicardi–Goutières–like phenotypes exhibit heightened dependency on certain helicases (e.g., POLQ, WRN, DDX5). This provides highly selective cancer-specific vulnerabilities.

2. Helicase Structure Provides Multiple Druggable Sites

Including:

• ATP-binding pockets
• RNA/DNA binding channels
• Auxiliary domains (Winged helix, OB folds)
• Protein–protein interaction sites
• Allosteric regulatory modules

This diversity expands medicinal chemistry possibilities.

3. Helicase Activity Is Enzymatic and Quantifiable

This makes biochemical assays ideal for:

• HTS primary screening
• Kinetic profiling
• Mechanism-of-action determination
• Inhibitor IC₅₀ and EC₅₀ quantification

4. RNA and DNA Substrate Selectivity Enables Unique Mechanisms

Some inhibitors affect:

• ATPase activity
• Unwinding activity
• Nucleic acid specificity
• Cofactor dependence (e.g., RIG-I ligands)

5. Helicases Are Central Nodes in Stress Pathways

They sit at convergence points for replication stress, immune activation, ribosome biogenesis, and RNA metabolism — all druggable disease pathways.

How to Screen for Helicase Inhibitors: Biochemical Assay Strategies

Drug discovery campaigns for helicase targets usually incorporate two orthogonal biochemical readouts:

Measuring ATP Hydrolysis with the Transcreener® ADP² Assay

Nearly all helicases use ATP hydrolysis to fuel unwinding. BellBrook’s Transcreener ADP² Assay is a universal, non-coupled HTS assay that detects ADP produced during ATP turnover.

Transcreener Benefits for Helicase Screens

• Direct detection of ADP
• No coupling enzymes → lower interference
• Suitable for low ATP turnover rates common in helicases
• 3 detection modes: FP, FI, TR-FRET
• Validated for 384- and 1536-well uHTS
• Robust Z’ factors (≥0.7–0.9) for helicase assays

Ideal for Helicases Including:

• DHX9
• DDX3
• DDX5
• DDX41
• MDA5
• RIG-I
• POLQ
• WRN (ATPase domain)

Because helicase ATP consumption often depends on RNA or DNA substrates, Transcreener enables evaluation of:

• substrate specificity
• cofactor dependence
• kinetic properties
• inhibitor competition profiles

Measuring Duplex Unwinding with the Heliscreener Assay

Some helicases exhibit weak ATPase activity but strong unwinding activity. Others show differential sensitivity to inhibitors depending on the readout.

Heliscreener Measures:

• separation of fluorescently labeled RNA duplexes
• fluorescence dequenching upon strand liberation
• real-time or endpoint unwinding activity

Advantages for Drug Discovery

• Directly measures the biological function (unwinding)
• Fast reaction setup
• Highly sensitive fluorescence signal
• Excellent for orthogonal confirmation
• Detects inhibitors that do not affect ATP turnover

Helicases Commonly Run on Heliscreener:

• DHX9
• DDX3
• DDX5
• DDX21
• DDX1
• DDX17

Integrating ATPase + unwinding assays helps distinguish:

• ATP competitive inhibitors
• nucleic acid-binding disruptors
• allosteric inhibitors
• functionally selective modulators

Deep Dive: Key BellBrook-Supported Helicase Targets

Below are expanded profiles of helicases that are high-value drug targets and are directly compatible with Transcreener and Heliscreener assays.

DHX9: A Central Player in R-Loop Biology and Cancer

Indications: breast cancer, ovarian cancer, Ewing sarcoma, viral oncogenesis
Functions:

• unwinds RNA:DNA hybrids
• regulates transcription
• resolves R-loops
• supports genome stability

Why It’s Drug-Relevant:
Tumors with R-loop accumulation rely on DHX9 to avoid catastrophic DNA damage. Inhibition induces synthetic lethality in R-loop-high cancers.

Assay Compatibility:

• ATPase → Transcreener ADP²
• Unwinding → Heliscreener

DHX9 is one of the strongest dual-assay helicases in the BellBrook portfolio.

Learn more about DHX9 Assays.

DDX3: A Multifunctional Helicase in Cancer and Viral Disease

Indications: medulloblastoma, hepatocellular carcinoma, HIV, hepatitis C
Functions:
translation, RNA remodeling, innate immunity, stress granule assembly

Assay Compatibility:

• ATPase → Transcreener ADP²
• Unwinding → Heliscreener

Learn more about DDX3X Assays.

DDX5: R-Loop Regulator and Hormone-Driven Cancer Target

Indications: breast cancer, prostate cancer, leukemia
Functions:
transcriptional regulation, microRNA processing, R-loop control

Assay Compatibility:

• ATPase → Transcreener ADP²
• Unwinding → Heliscreener

Learn more about DDX5 Assays.

POLQ: A Breakthrough Oncology Target for BRCA-Deficient Tumors

Indications: HR-deficient cancers, ovarian cancer, TNBC
Functions:
helicase + polymerase activity used in microhomology-mediated end joining

Why It’s Important:
POLQ inhibitors are considered the next PARP inhibitors for BRCA-mutant cancers.

Assay Compatibility:

• High ATPase activity → Transcreener ADP²

Learn more about POLQ Assays.

MDA5 & RIG-I: RNA-Sensing Helicases for Immunomodulation

Indications: antiviral therapies, autoimmune disease, immuno-oncology
Functions:
detect viral RNA and trigger type I interferon production

Assay Compatibility:
ATPase activity → Transcreener

Learn more about MDA5 and RIG-I Assays.

DDX41

Indications: myeloid malignancies, inflammasome-related autoinflammatory disease
Functions:
cytosolic DNA sensing, innate immune signaling

Assay Compatibility:
ATPase-dependent → Transcreener ADP²

Learn more about DDX41 Assays.

Building an Effective Screening Cascade for Helicase Drug Discovery

An optimized helicase screening campaign typically includes:

Step 1: ATPase Primary Screen (Transcreener ADP²)

• Broad, robust, HTS-ready
• Detects ATP competition, allosteric inhibition
• Supports large screens and diversity sets

Step 2: Orthogonal Unwinding Confirmation (Heliscreener)

• Confirms inhibition of the biological function
• Eliminates ATPase-only artifacts

Step 3: Dose-Response and Mechanistic Profiling

• IC₅₀ for ATPase
• IC₅₀ for unwinding
• Substrate competition assays
• Mutant helicase selectivity studies

Step 4: Secondary Cell-Based Confirmation

• R-loop accumulation (for DDX5/DDX21/DHX9)
• IFN activation (for RIG-I/MDA5)
• DNA damage markers (for POLQ/WRN targets)

The integration of both BellBrook platforms creates a best-in-class workflow for helicase inhibitor discovery.

Why Transcreener and Heliscreener Are Excellent for Helicase Screening

1. Direct Detection = Lower Interference

No coupling enzymes → fewer false positives.

2. High Sensitivity for Low-Turnover Enzymes

Helicases often have slow ATPase rates; Transcreener’s sensitivity excels here.

3. Universal Compatibility

Transcrener works with almost any helicase, RNA/DNA substrate, or reaction buffer.

4. Suitable for uHTS (1536-well)

Researchers can confidently run 100K–1M compound screens.

5. Orthogonality Reduces Artifacts

Running both assays prevents ATPase-only or unwinding-only false hits.

6. Flexible Detection Modes

FP, FI, or TR-FRET based on plate reader capabilities.

Conclusion: Helicases Are Entering a New Era of Drug Discovery

With the rise of synthetic lethality, immuno-oncology, and RNA-targeted therapies, helicases are becoming some of the most sought-after targets in pharma pipelines. Their multifunctional roles in genome stability and immune regulation create expansive therapeutic opportunities—ranging from antiviral therapies to next-generation cancer treatments.

Biochemical assay technologies such as Transcreener ADP² and Heliscreener Unwinding are now enabling reliable, high-throughput discovery of helicase inhibitors. These platforms allow researchers to interrogate ATPase and unwinding activity with precision, dramatically reducing false positives and accelerating hit-to-lead progression.

As more helicase structures are solved, and more disease-relevant dependencies are discovered, the field is poised for rapid expansion—and BellBrook Labs is positioned at the center of this momentum.

FAQs

What are helicases and why are they drug targets?

Helicases are ATP-dependent nucleic acid unwinding enzymes essential for DNA repair, replication, transcription, and innate immunity. Their central role in genome maintenance makes them strong oncology and antiviral targets.

Which helicases are most promising for cancer drug discovery?

Top oncology helicases include POLQ, WRN, BLM, FANCJ, DDX3, DDX5, and DHX9.

How do you screen for helicase inhibitors?

Using biochemical assays such as the Transcreener ADP assay (ATPase measurement) and Heliscreener RNA unwinding assay (direct unwinding measurement).

What assays work best for helicase HTS?

Transcreener ADP² for ATP turnover and Heliscreener for unwinding provide orthogonal, HTS-validated readouts.

What role do helicases play in DNA repair?

They regulate homologous recombination, replication fork progression, R-loop resolution, and telomere stability.